# Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis

Study · id `cardio:ct-nct02814409` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02814409](<https://clinicaltrials.gov/study/NCT02814409>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02814409

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1858 participants.

## Technical summary

Registry record NCT02814409. Randomized; no masking; primary purpose treatment. Start 2016-12-15 (actual); primary completion 2023-08-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1858 participants (enrolled count; ClinicalTrials.gov record NCT02814409, source copy `cardio:ctgov-nct02814409-2024-06-13`, retrieved 2026-10-26)
- Started: 2016-12-15 (actual) (ClinicalTrials.gov record NCT02814409, source copy `cardio:ctgov-nct02814409-2024-06-13`, retrieved 2026-10-26)
- Primary completion: 2023-08-31 (actual) (ClinicalTrials.gov record NCT02814409, source copy `cardio:ctgov-nct02814409-2024-06-13`, retrieved 2026-10-26)
- Completion: 2024-01-10 (actual) (ClinicalTrials.gov record NCT02814409, source copy `cardio:ctgov-nct02814409-2024-06-13`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT02814409, source copy `cardio:ctgov-nct02814409-2024-06-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02814409-2024-06-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis
- Acronym: ATTEST2
- Condition: Ischemic Stroke
- Intervention (Drug): Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase
- Intervention (Drug): Intravenous Tenecteplase
- Lead sponsor: NHS Greater Glasgow and Clyde
- Lead sponsor class: OTHER
- Collaborator: University of Glasgow
- Collaborator class: OTHER
- Collaborator: University of Edinburgh
- Collaborator class: OTHER
- Collaborator: Oxford University Hospitals NHS Trust
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: NHS Greater Glasgow and Clyde (`cardio:org-nhs-greater-glasgow-and-clyde`)
- Registry lists this organization as a collaborator: University of Glasgow (`cardio:org-university-of-glasgow`)
- Registry lists this organization as a collaborator: University of Edinburgh (`cardio:org-university-of-edinburgh`)
- Registry lists this organization as a collaborator: Oxford University Hospitals NHS Trust (`cardio:org-oxford-university-hospitals-nhs-trust`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial (`cardio:pubmed-39424558`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 42154b17797701ef4a1b090435a34752f6c7144fbaffad757ef9de4799456ec2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
